Robert M. Clancy

This study defines the single-cell landscape of Class II lupus nephritis and identifies fibroblast transcriptional programs and chronicity index as potential predictors of kidney outcomes.

The paper uses serum proteomics to identify molecular signatures that classify lupus nephritis, differentiate disease activity and chronicity, and predict treatment response.

This study uses single-cell RNA-sequencing and spatial transcriptomics to analyze myeloid cell dynamics in lupus nephritis, showing shifts in immune responses linked to disease progression.

The paper identifies three immunologically distinct groups in lupus nephritis patients based on blood immunophenotyping, correlating with histopathology, treatment response, and renal outcomes.